RxDoctor Payments Data

Francesco Santucci, MD

Internal Medicine · Pittsburgh, PANPI 1740255033

Payments from drug & device makers

$535in general payments, 2019–2025

Across 28 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$98
  • Abbott$59
  • AbbVie$48
  • Regeneron Healthcare Solutions, Inc.$35
  • Astellas Pharma US Inc$34
  • Vanda Pharmaceuticals Inc.$33
  • plus $227 from 11 others

What the payments were for

  • Food & beverage$535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$535 in reported general payments places this provider in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$59,589
Medicare patients
148
Services billed
596

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$75,861
EliquisApixaban68$53,951
XareltoRivaroxaban51$42,257
JardianceEmpagliflozin45$41,517
JanuviaSitagliptin Phosphate26$27,754
MounjaroTirzepatide22$24,044
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,350
TrulicityDulaglutide13$14,179
LinzessLinaclotide14$8,387
Atorvastatin Calcium297$2,534
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$2,436
Rosuvastatin Calcium120$2,266
Phenobarbital12$1,896
Levothyroxine Sodium119$1,604
FenofibrateFenofibrate Nanocrystallized23$1,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$30$75,86172 claims
PfizerEliquis$98$53,95168 claims
Boehringer IngelheimJardiance$17$41,51745 claims
GSKTrelegy Ellipta$21$16,35018 claims
AbbVieLinzess, Synthroid$48$9,82148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →